Shares of Danaher (DHR) surged 12.11% on Tuesday, following the company's impressive third-quarter earnings report that significantly exceeded analyst expectations. The life sciences and diagnostics company demonstrated robust performance, particularly in its bioprocessing business and respiratory market.

Danaher reported adjusted earnings per share of $1.89 for the third quarter, substantially beating the consensus estimate of $1.72. Revenue for the quarter came in at $6.1 billion, surpassing analysts' expectations of $6.007 billion. The company attributed its strong results to momentum in its bioprocessing business and higher-than-expected sales in its respiratory market, particularly at its Cepheid unit.

Despite the impressive quarterly results, Danaher maintained its full-year adjusted earnings guidance range of $7.70 to $7.80 per share. The company expects low-single digit core revenue growth for 2025 and anticipates a 2.5% sales increase from currency impact in the fourth quarter. Investors seem to be reacting positively to Danaher's ability to outperform in a challenging market environment, driving the stock's significant rally.